Evoke (+) trials of semaglutide for early alzheimer's disease: Innovations, lessons, and implications

More on Inflammation

• Semaglutide may protect kidneys by reducing vascular resistance

  Nature Medicine · 4 Oct 2026

  

• App knock-in mice display age-dependent Alzheimer's pathology

  bioRxiv · 4 Oct 2026

  

• Lifestyle trial found similar Alzheimer’s blood marker changes

  medRxiv · 7 Oct 2026

  

• GLP-1 receptor agonists link to lower stroke and Alzheimer risk

  Neurology Genetics · 4 Oct 2026